Status: Recruiting
Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Participants needed: 73
Trial details
Phase: Early Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: NeurosterixUpdated: Jan 15, 2026Locations: 1
Eligibility criteria
Male or non-pregnant, non-lactating female participants, ages 18-55 who are not... [+5]
(Part 1a/b, Part 2 Healthy): History of or current clinically significant medica... [+5]